Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:healthcare_organization
|
| gptkbp:activities |
inhibits lymphocyte proliferation
|
| gptkbp:appointed_by |
intravenous infusion
oral tablet |
| gptkbp:approves |
gptkb:1995
gptkb:FDA |
| gptkbp:brand |
Cell Cept
Myfortic |
| gptkbp:class |
benzoic acid derivative
|
| gptkbp:clinical_trial |
gptkb:psychologist
gptkb:rheumatoid_arthritis liver transplant lupus nephritis heart transplant kidney transplant |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dissolved |
soluble in water
soluble in ethanol |
| gptkbp:dosage_form |
500 mg twice daily
1 g twice daily |
| https://www.w3.org/2000/01/rdf-schema#label |
mycophenolate mofetil
|
| gptkbp:ingredients |
C23 H31 N1 O7
|
| gptkbp:interacts_with |
antacids
other immunosuppressants cholestyramine |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
treating autoimmune diseases
preventing organ rejection |
| gptkbp:lifespan |
16 to 18 hours
|
| gptkbp:manager |
IV
oral |
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea hypertension gastrointestinal bleeding diarrhea insomnia skin rash thrombocytopenia alopecia hyperglycemia increased risk of infection leukopenia |
| gptkbp:traded_on |
Cell Cept
Myfortic |